Price movement over the last 24 hours
ADMA Biologics Inc vs ARK Next Generation Internet ETF — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while ARK Next Generation Internet ETF trades at $144.89. The key difference: ARK Next Generation Internet ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ARKW | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $182.20 |
52-Week Low | $7.60 | $114.45 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ARKW is trading at $150.00, up 3.32% with strong technical momentum showing bullish moving averages and key indicators like ADX signaling upward trend strength. The stock faces resistance near $151-152 with support at $144-142. Recent news highlights ARK Invest's Cathie Wood sharing investments in Magnificent Seven stocks with Bill Ackman, indicating institutional confidence in growth-oriented technology holdings.
The ETF's exposure to innovative technology companies presents growth potential amid AI and digital transformation trends. Key risks include concentration in volatile tech sectors and market sensitivity to interest rate changes. Current technical strength suggests near-term upside potential if resistance levels are breached.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →